Scope of report
- The report provides a snapshot of the global therapeutic landscape of Idiopathic pulmonary fibrosis.
- The report assesses Idiopathic pulmonary fibrosis pipeline based on highest phase of development, type of sponsor, mechanism of action (MoA), route of administration (RoA), and molecule type.
- The report reviews Idiopathic pulmonary fibrosis pipeline by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The report covers pipeline products based on various stages of development for Idiopathic pulmonary fibrosis ranging from discovery to pre-registration and undisclosed stages.
DS Biopharma, Boehringer Ingelheim, Samumed, MSM Protein Technologies, Ribomic, FibroStatin, StemMed, HEC Pharm, mondoBIOTECH, Nuevolution, Chiesi, Glenmark Pharmaceuticals Ltd, Respira Therapeutics, NuMedii, Abeome Corporation, Proterris, RespiVert, Asahi Kasei Pharma Corp
Pirfenidone, Pamrevlumab, AEOL 10150, Sonolisib, Nintedanib, Tipelukast, Lebrikizumab, STX 100, Carlumab, Dectrekumab, Tanzisertib, PBI 4050, PRM 151, Omipalisib, BMS 986020, SAR 156597, Collagen type V oral solution, Acetylcysteine/pentoxifylline, KD 025
Format: Microsoft Excel
- Single Use: $300
- Site License: $500
- Global License: $800